AI Based Real Time Detection of Endometriosis Lesions
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Mar 6, 2025
Trial Information
Current as of April 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining a new way to help doctors detect endometriosis, a condition where tissue similar to the lining of the uterus grows outside of it. Researchers are developing an artificial intelligence (AI) tool that can automatically identify endometriosis lesions using images and videos taken during surgery. This AI-based approach aims to improve the accuracy and speed of diagnosis, which could lead to better treatment for patients.
To participate in this trial, women aged 18 and older who are scheduled to have surgery for endometriosis can apply. Participants will be asked to give their written consent, meaning they agree to take part after understanding what the study involves. It’s important to note that patients should be able to follow instructions and understand the trial's purpose. Those with other cancers or who cannot give consent will not be eligible. If you qualify and choose to participate, you can expect to help in the development of new technology that could make diagnosing endometriosis easier for future patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Written consent after explanation
- • Indication for surgical treatment of endometriosis
- Exclusion Criteria:
- • Expected lack of patient compliance or inability of the patient to understand the purpose of the clinical trial
- • Absence of patient consent
- • Malignancies
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tübingen, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported